Regeneron and Bluebird Bio have announced that they will collaboration to apply their respective technology platforms to the discovery, development and commercialisat...

A synthetic chemical (KHS101) has been discovered by researchers that has the ability to kill aggressive brain tumour cells by removing their source of energy. This ...

Regulatory T cells, or Tregs, ensure our immune responses don’t spin out of control and can cause autoimmune diseases. But on the flip side, they can also limit the p...

The European Medicines Agency's necessary relocation to Amsterdam following the U.K.'s Brexit vote has moved into its next phase with a business continuity plan "aime...

Epizyme is scaling back research on its lead drug as a treatment for a type of blood cancer after reviewing discouraging data, the company announced Thursday in its s...

Research published in Nature Medicine describes collaborative effort to reduce off-target CRISPR-Cas9 genome editing – removing barriers for human therapeutic applica...

Laekna has signed an agreement with Novartis Pharma to develop and commercialize two oral Novartis clinical-stage oncology assets. Laekna Inc., a biotechnology compa...

Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based biotech unveiled the series A round alongside the ap...

The ability to identify women who face the highest risk of triple-negative breast cancer could save lives, but only one inherited mutation—in the gene BRCA1—has been ...

The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer. Regeneron Pharmaceuticals and bluebird bio announce...